Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CELOPHIN: Allogeneic ASCs for Cicatricial Conjunctivitis
NCT05520086Phase 2Unknown
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
- Start
- Nov 2022
- Primary completion
- Jun 2024
- Modality
- Hydrogel Systems, Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of allogeneic adipose-derived mesenchymal stem cells + fibrin gel in Cicatricial conjunctivitis, mucous membrane pemphigoid (MMP), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), sponsored by Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz. Status: unknown.
02
Drugs
allogeneic adipose-derived mesenchymal stem cells + fibrin gel
03
Conditions
Cicatricial conjunctivitismucous membrane pemphigoid (MMP)Stevens-Johnson syndrome (SJS)toxic epidermal necrolysis (TEN)
Beyond the preview
Go deeper on NCT05520086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05520086.